Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Net Margin (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Net Margin for 10 consecutive years, with 62.02% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin rose 1949.0% to 62.02% in Q4 2025 year-over-year; TTM through Dec 2025 was 85.44%, a 1635.0% increase, with the full-year FY2025 number at 85.44%, up 1635.0% from a year prior.
  • Net Margin was 62.02% for Q4 2025 at Ultragenyx Pharmaceutical, up from 112.81% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 62.02% in Q4 2025 to a low of 270.23% in Q3 2022.
  • A 5-year average of 132.41% and a median of 138.87% in 2021 define the central range for Net Margin.
  • Biggest YoY gain for Net Margin was 19084bps in 2021; the steepest drop was -18179bps in 2021.
  • Ultragenyx Pharmaceutical's Net Margin stood at 149.65% in 2021, then increased by 2bps to 146.91% in 2022, then skyrocketed by 34bps to 97.17% in 2023, then rose by 16bps to 81.51% in 2024, then grew by 24bps to 62.02% in 2025.
  • Per Business Quant, the three most recent readings for RARE's Net Margin are 62.02% (Q4 2025), 112.81% (Q3 2025), and 69.04% (Q2 2025).